top of page
DrugCard

DrugCard

Unclaimed profile

No ratings yet

​

AI-powered pharmacovigilance automation for global and local literature monitoring and regulatory intelligence.

AI Categories:

x

Pricing Model:

Contact for Pricing

Follow:

Latest Updates

Similar tools

Similar tools count
Otter.ai

0

average rating is 3 out of 5, based on 150 votes, Ratings

Otter.ai

Freemium

#

Automates meeting notes with real-time transcription.

InSummary

0

average rating is 3 out of 5, based on 150 votes, Ratings

InSummary

Free

#

AI-powered tool delivering non-intrusive, real-time productivity insights.

Tailor

0

average rating is 3 out of 5, based on 150 votes, Ratings

Tailor

Free

#

Revolutionizes news consumption with AI-driven, personalized daily summaries.

PDF.ai

0

average rating is 3 out of 5, based on 150 votes, Ratings

PDF.ai

Free Trial

#

Transform PDF interactions with AI: chat, extract data, summarize, secure handling.

Comments

Share Your ThoughtsBe the first to write a comment.

About DrugCard

Overview of DrugCard

DrugCard is an Estonian technology company specializing in pharmacovigilance automation. The company develops an AI-powered platform for automated medical literature screening, regulatory intelligence, and drug safety monitoring. DrugCard covers 121+ countries and monitors over 2,200 local journals not indexed in global databases such as PubMed, reducing literature screening time by up to 70% compared to manual processes. The platform serves pharmaceutical companies, contract research organizations (CROs), and marketing authorization holders (MAHs). In addition to its software, DrugCard offers managed pharmacovigilance services including local and global literature screening, case processing, signal detection, and regulatory writing. Founded in 2021 and headquartered in Tallinn, Estonia, the company has grown to 30 employees and serves clients across Europe, the Middle East, and Asia.

Key Features

About the tool

I'm a paragraph. Click here to add your own text and edit me. It's easy.

bottom of page